Overview

Safety and Tolerability of 28 Days Treatment With Glycopyrronium Bromide (NVA237) (100 or 200 µg Once a Day) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Status:
Completed

Trial end date:
2008-01-01

Target enrollment:

Participant gender:

Summary

This study assessed the safety/tolerability of 28 days of treatment with NVA237 100 µg and 200 µg once a day, compared to placebo in patients with moderate or severe Chronic Obstructive Pulmonary Disease (COPD).

Phase:

Phase 2

Details

Lead Sponsor:

Novartis

Treatments:

Bromides
Glycopyrrolate